| 小分子p53-MDM2抑制剂先导化合物苄普地尔的研究 |
| 投稿时间：2020-09-15 修订日期：2021-03-07 点此下载全文 |
| 引用本文：罗川,李锦,张万年,缪震元.小分子p53-MDM2抑制剂先导化合物苄普地尔的研究[J].药学实践杂志,2021,39(2):126~129 |
| 摘要点击次数: 1008 |
| 全文下载次数: 807 |
|
| 基金项目:国家自然科学基金（81373331） |
|
| 中文摘要:目的 采用老药新用药物设计方法，探寻p53-MDM2蛋白结合小分子抑制剂的先导化合物。方法 通过荧光偏振（FP）法和蛋白印迹试验法，分别测定化合物的p53-MDM2蛋白结合抑制活性和相关蛋白的表达变化，采用四甲基偶氮唑盐微量酶反应比色法（MTT法）测试其体外抗肿瘤活性，并且测定人肝微粒体中代谢产物。结果 发现苄普地尔具有优秀的体外抗肿瘤活性和较强的p53-MDM2蛋白结合抑制活性，能显著降低MDM2蛋白的表达，而且呈剂量依赖性。在人肝微粒体中的代谢产物主要为苯环羟基单氧化代谢产物。结论 苄普地尔可作为p53-MDM2蛋白结合小分子抑制剂先导化合物，用于后续的结构优化设计研究。 |
| 中文关键词:老药新用 药物设计 苄普地尔 p53-MDM2蛋白结合抑制剂 |
| |
| Discovery of bepridil as a valuable lead compound with potent p53-MDM2 inhibitory activity |
|
|
| Abstract:Objective To find novel lead compounds as p53-MDM2 inhibitors by drug repurposing strategy.Methods The p53-MDM2 inhibitory activities of compounds were determined by FP and western blotting. MTT method was used to determine the in-vitro antitumor activities. The metabolites in human liver microsomes were tested.Results Bepridil showed excellent in-vitro anti-tumor activity and strong p53-MDM2 protein binding inhibitory activity, which can significantly reduce the expression of MDM2 protein in a dose-dependent manner. The metabolites in human liver microsomes are mainly benzene ring hydroxyl mono-oxidation metabolites.Conclusion Bepridil can be used as a lead compound for p53-MDM2 protein binding small molecule inhibitors for subsequent structural optimization design studies. |
| keywords:new uses of old drugs strategy drug design bepridil p53-MDM2 inhibitor |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
